|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, while PARP inhibitors have demonstrated a clear role in treating tumors with underlying homologous recombination deficiencies, there is now biological and early clinical evidence to support their use in other molecular subsets of cancer, including tumors associated with high levels of replication stress such as small-cell lung cancer.
|
30760478 |
2019 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?
|
31575562 |
2019 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Small-cell lung cancer (SCLC) is an aggressive malignancy in which inhibitors of PARP have modest single-agent activity.
|
31416802 |
2019 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further large-scale clinical studies are urgently needed for a better designation of PARP inhibitors and Rova-T in the therapeutic algorithm of SCLC patients.
|
31148500 |
2019 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study examined safety, pharmacokinetics, and efficacy of veliparib, a PARP inhibitor, combined with carboplatin and etoposide in patients with extensive-stage (ED) small cell lung cancer (SCLC) and other solid tumors.
|
30327308 |
2019 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
SIGNIFICANCE: Our results define previously unrecognized immunomodulatory functions of DDR inhibitors and suggest that adding PARP or CHK1 inhibitors to ICB may enhance treatment efficacy in patients with SCLC.
|
30777870 |
2019 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Following our development of circulating tumor cell patient-derived explants (CDX) as models that faithfully mirror patient disease, here we exploit CDX to examine new therapeutic options for SCLC.<b>Experimental Design:</b> We investigated the efficacy of the PARP inhibitor olaparib alone or in combination with the WEE1 kinase inhibitor AZD1775 in 10 phenotypically distinct SCLC CDX <i>in vivo</i> and/or <i>ex vivo</i> These CDX represent chemosensitive and chemorefractory disease including the first reported paired CDX generated longitudinally before treatment and upon disease progression.<b>Results:</b> There was a heterogeneous depth and duration of response to olaparib/AZD1775 that diminished when tested at disease progression.
|
29941481 |
2018 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Poly ADP-ribose polymerase-1 (PARP1) is overexpressed in SCLC and response to PARP inhibitors have been reported in patients with SCLC.
|
29570891 |
2018 |
|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Initial trials with PARP inhibitors have shown promising activity in some SCLC patients.
|
30203184 |
2018 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Target engagement imaging of PARP inhibitors in small-cell lung cancer.
|
29330466 |
2018 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer.
|
30354077 |
2018 |
|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PARP inhibitors, especially those with high PARP trapping activity, may provide a powerful tool to improve the efficacy of radiotherapy in SCLC.<i></i>.
|
29945991 |
2018 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy of PARP inhibitors olaparib, rucaparib, and veliparib, as well as etoposide and cisplatin in SCLC cell lines, and gene expression correlates, was analyzed using public datasets.
|
27440269 |
2017 |
|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Treatment with cisplatin or PARP inhibitors downregulated SLFN11 and E-cadherin, possibly explaining the rapid development of therapeutic resistance in SCLC.
|
28212573 |
2017 |